RxDoctor Payments Data

Mark Gallardo, MD

Dermatology · Hattiesburg, MSNPI 1336159607

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,029 of the $15,196 with a category attached, or 66.0%. 40 manufacturers reported payments, led by Glaukos Corporation at 32.9% of the total. Reporting peaked in 2019 at $6,138 and has fallen 74.2% since, to $1,581 in 2025.

$15,196in general payments, 2019–2025

Across 661 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$5K
  • Novartis$2K
  • AbbVie$1K
  • Sanofi$708
  • Johnson & Johnson$572
  • Incyte Corporation$556
  • plus $5K from 34 others

What the payments were for

  • Grants$5,00033%
  • Food & beverage$10,02966%
  • Education$1671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,196 in reported general payments places this provider in the 80th percentile of 78 dermatology providers in Mississippi.

See all dermatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$647,131
Medicare patients
1,753
Services billed
31,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab23$298,061
Cosentyx Sensoready (2 Pens)Secukinumab27$199,997
TremfyaGuselkumab13$178,003
OtezlaApremilast22$103,507
HumiraAdalimumab14$99,409
EnbrelEtanercept13$95,658
AdbryTralokinumab-Ldrm24$86,305
SiliqBrodalumab13$62,175
Metronidazole90$7,316
Fluocinonide62$4,306
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc36$3,245
Mometasone Furoate101$3,221
Betamethasone Valerate52$2,869
Ketoconazole145$2,682
Desonide35$2,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$412$199,16535 claims
Johnson & JohnsonTremfya$572$178,00313 claims
AbbVieHumira$1,362$99,40914 claims
LEO Pharma Inc.Adbry$487$86,30524 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq$380$62,17513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 78 dermatology providers in Mississippi.

Other dermatology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →